PAHC Stock Analysis: Phibro Animal Health | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.403m USD | 12M Return: -8.3% | US71742Q1067 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.70M
EPS Trend: 98.1%
Qual. Beats: 4
Rev. Trend: 97.5%
Qual. Beats: 5
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Phibro Animal Health Corporation is a U.S.-based animal health and mineral nutrition company that operates across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company runs three reporting segments: Animal Health, Mineral Nutrition, and Performance Products, serving both livestock producers and companion animal markets.
The companys product portfolio includes antibacterials, anticoccidials, nutritional specialty products, vaccines (both conventionally licensed and autogenous), and vaccine adjuvants for poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also manufactures microbial and bioproducts for environmental, industrial, and agricultural applications, trace mineral formulations (zinc, copper, manganese, iron) for livestock feed fortification, and specialty ingredients used in personal care and industrial chemical industries.
Distribution occurs through local sales offices, integrated livestock producers, commercial animal feed manufacturers, wholesalers, and distributors. The company was founded in 1946 as Philipp Brothers Chemicals, Inc., adopted its current name in 2003, and is headquartered in Teaneck, New Jersey.
As a player in the animal pharmaceuticals and nutrition space, Phibro addresses the growing global demand for protein and the parallel rise in livestock health spending, while its Performance Products segment diversifies the business model beyond core animal health into industrial and specialty chemical end markets.
- Animal Health segment growth driven by vaccines and specialty nutrition
- High leverage and interest costs continue pressuring profit margins
- Antibiotic regulations and livestock production cycles shape end-market demand
| Net Income: 99.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.42 > 1.0 |
| NWC/Revenue: 40.78% < 20% (prev 39.90%; Δ 0.88% < -1%) |
| CFO/TA 0.05 > 3% & CFO 69.0m > Net Income 99.7m |
| Net Debt (762.7m) to EBITDA (236.5m): 3.23 < 3 |
| Current Ratio: 2.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.0m) vs 12m ago 0.74% < -2% |
| Gross Margin: 33.76% > 18% (prev 30.85%; Δ 2.91% > 0.5%) |
| Asset Turnover: 106.1% > 50% (prev 95.25%; Δ 10.83% > 0%) |
| Interest Coverage Ratio: 3.89 > 6 (EBIT TTM 184.9m / Interest Expense TTM 47.6m) |
| A: 0.41 (Total Current Assets 935.5m - Total Current Liabilities 316.5m) / Total Assets 1.50b |
| B: 0.24 (Retained Earnings 353.0m / Total Assets 1.50b) |
| C: 0.13 (EBIT TTM 184.9m / Avg Total Assets 1.43b) |
| D: 0.35 (Book Value of Equity 385.5m / Total Liabilities 1.12b) |
| Altman-Z'' = 4.70 = AA |
| DSRI: 0.89 (Receivables 238.8m/228.0m, Revenue 1.52b/1.30b) |
| GMI: 0.91 (GM 30.85% / 33.76%) |
| AQI: 1.16 (AQ_t 0.13 / AQ_t-1 0.11) |
| SGI: 1.17 (Revenue 1.52b / 1.30b) |
| TATA: 0.02 (NI 99.7m - CFO 69.0m) / TA 1.50b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 34.45 with a total of 206,581 shares traded. Over the past week, the price has changed by -0.32%, over one month by -3.82%, over three months by +8.57% and over the past year by -8.31%.
Current recommended Stop Loss: 32.80 (which is 4.8% or 1.2 ATR below the current price).
Phibro Animal Health has received a consensus analysts rating of 2.50. Therefore, it is recommended to sell PAHC.
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 44 | 27.7% |
P/E Trailing = 14.1639
P/E Forward = 13.8313
P/S = 0.9243
P/B = 3.6259
P/EG = 1.6791
Revenue TTM = 1.52b USD
EBIT TTM = 184.9m USD
EBITDA TTM = 236.5m USD
Long Term Debt = 707.8m USD (from longTermDebt, last quarter)
Short Term Debt = 35.6m USD (from shortTermDebt, last quarter)
Debt = 844.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 56.0m
Net Debt = 762.7m USD (calculated: Debt 844.7m - CCE 82.0m)
Enterprise Value = 2.17b USD (1.40b + Debt 844.7m - CCE 82.0m)
Interest Coverage Ratio = 3.89 (Ebit TTM 184.9m / Interest Expense TTM 47.6m)
EV/FCF = 219.5x (Enterprise Value 2.17b / FCF TTM 9.87m)
FCF Yield = 0.46% (FCF TTM 9.87m / Enterprise Value 2.17b)
FCF Margin = 0.65% (FCF TTM 9.87m / Revenue TTM 1.52b)
Net Margin = 6.57% (Net Income TTM 99.7m / Revenue TTM 1.52b)
Gross Margin = 33.76% ((Revenue TTM 1.52b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 33.88% (prev 32.77%)
Tobins Q-Ratio = 1.44 (Enterprise Value 2.17b / Total Assets 1.50b)
Interest Expense / Debt = 5.64% (Interest Expense 47.6m / Debt 844.7m)
Taxrate = 27.40% (37.6m / 137.3m)
NOPAT = 134.3m (EBIT 184.9m * (1 - 27.40%))
Current Ratio = 2.96 (Total Current Assets 935.5m / Total Current Liabilities 316.5m)
Debt / Equity = 2.19 (Debt 844.7m / totalStockholderEquity, last quarter 385.5m)
Debt / EBITDA = 3.23 (Net Debt 762.7m / EBITDA 236.5m)
Debt / FCF = 77.31 (Net Debt 762.7m / FCF TTM 9.87m)
Total Stockholder Equity = 347.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.97% (Net Income 99.7m / Total Assets 1.50b)
RoE = 28.67% (Net Income TTM 99.7m / Total Stockholder Equity 347.8m)
RoCE = 17.52% (EBIT 184.9m / Capital Employed (Equity 347.8m + L.T.Debt 707.8m))
RoIC = 11.73% (NOPAT 134.3m / Invested Capital 1.14b)
WACC = 7.73% (E(1.40b)/V(2.25b) * Re(9.92%) + D(844.7m)/V(2.25b) * Rd(5.64%) * (1-Tc(0.27)))
Discount Rate = 9.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.89 | Cagr: 0.52%
[DCF] Terminal Value 73.10% ; FCFF base≈22.7m ; Y1≈19.9m ; Y5≈16.0m
[DCF] Fair Price = N/A (negative equity: EV 257.6m - Net Debt 762.7m = -505.1m; debt exceeds intrinsic value)
EPS Correlation: 98.14 | EPS CAGR: 54.25% | SUE: 2.63 | # QB: 4
Revenue Correlation: 97.54 | Revenue CAGR: 21.03% | SUE: 1.83 | # QB: 5
EPS current Quarter (2026-09-30): EPS=0.77 | Chg30d=-2.89% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-12-31): EPS=0.97 | Chg30d=+6.14% | Revisions=+25% | Analysts=3
EPS current Year (2027-06-30): EPS=3.50 | Chg30d=+4.70% | Revisions=+62% | GrowthEPS=+8.7% | GrowthRev=+3.8%
EPS next Year (2028-06-30): EPS=3.85 | Chg30d=+4.47% | Revisions=+57% | GrowthEPS=+10.0% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +64% (up=10, down=1)